Navigation Links
A Novel, Quantitative Immunohistochemistry Method Enabled by BioGenex IHC System
Date:2/17/2017

FREMONT, Calif., Feb. 17, 2017 /PRNewswire/ -- BioGenex, a global leader in molecular pathology, is pleased to announce development of a novel system for quantitative immunohistochemistry (IHC). The system was developed in collaboration with the University of Rochester (NY, USA) and Konica-Minolta Inc. (Tokyo, Japan). The new system is able to accurately quantify the expression of an important breast cancer biomarker, HER2 (Human epidermal growth factor receptor-2) in clinical samples. Quantitative IHC is achieved by combining BioGenex IHC system with Konica-Minolta PID nanoparticles detection system (1). According to the study presented at the 2016 San Antonio Breast Cancer Symposium (SABCS), the new method is more accurate and shows a broader dynamic range of values when compared with IHC quantitation. When compared to FISH analysis, PID score/cell showed a much better correlation (R2=0.72) as compared to standard IHC (R2=0.41). Moreover, by using BioGenex Xmatrx-Infinity workstation, quantitative IHC can be fully automated with high precision, as demonstrated by Standard deviation (SD) values below 12%. This novel method offers great potential for the quantitative measurement of biomarkers to advance precession medicine for cancer and possible other diseases using tissue and cytology specimen. Further development work is required to bring this technology to molecular pathology laboratory for clinical application. The study results are available for download here.

"Once again we demonstrate our ability to deliver cutting edge technology to solve unmet medical needs years ahead of our competition," said Dr. Krish Kalra, founder and CEO of BioGenex.

HER2 Quantitation in Clinical Breast Cancer Samples
HER2 Quantitation in Clinical Breast Cancer Samples
Correlation between PID score/cell and Antibody-Binding Capacity in 8 breast cancer cell lines by FACS analysis (R2=0.94)
Correlation between PID score/cell and Antibody-Binding Capacity in 8 breast cancer cell lines by FACS analysis (R2=0.94)

HER2 overexpression in breast cancer is associated with an aggressive clinical course and poor outcome and was the first predictive IHC biomarker approved by the FDA (licensed in 1998). Targeting HER2 overexpression is a remarkably effective therapeutic modality (e.g. trastuzumab/Herceptin), however, inaccuracy of current HER2 testing methods can lead to non-optimal therapy with an estimated economic loss of about $1 billion annually.

About BioGenex: BioGenex designs, develops and commercializes molecular pathology systems for cancer diagnosis, prognosis, precession medicine and life science research. The recent introduction of our cytogenetic FISH workflow solution and miRNA system for characterization of Cancer of Unknown Primary (CUP) and undifferentiated tumors are a game changer and envy of the industry. Our fully-automated molecular pathology workstations are the most advanced system available globally. BioGenex prides itself on delivering cutting edge technology, years ahead of its competition, providing the finest systems for immunohistochemistry (IHC), In Situ hybridization (ISH), FISH, Special stains and in situ PCR. BioGenex unconditionally guarantees performance of its systems and products: antibodies, probes, antigen retrieval, detection systems and histology stains. We are committed to provide quality systems and best in class customer care.

www.biogenex.com

Corporate Communication
Krishan Kalra, PhD, BioGenex Founder and CEO
800-421-4149
146629@email4pr.com

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/a-novel-quantitative-immunohistochemistry-method-enabled-by-biogenex-ihc-system-300409127.html


'/>"/>
SOURCE BioGenex
Copyright©2017 PR Newswire.
All rights reserved


Related biology technology :

1. Alexi Venice’s Newly Released Second Novel, ‘SVEA’S SINS,’ is a Thriller About a 2018 Terrorist Plot Against the U.S. With Drones.
2. Resolution Bioscience announces successful collaboration on a novel, non-invasive, targeted NGS test for lung cancer
3. Lycera Announces Research Showing Novel, Oral Immunotherapy Possesses Potent Single Agent Anti-Cancer Activity
4. University of Illinois researchers demonstrate novel, tunable nanoantennas
5. Applied BioMath, LLC and CytomX Therapeutics, Inc. announce a collaboration to develop a Quantitative Systems Pharmacology Probody platform model for use in lmmuno-Oncology
6. Shimadzu’s New High-Sensitivity GCMS Offers Outstanding Qualitative/Quantitative Performance and Exceptional Reliability
7. Charm Sciences Achieves Independent Validation of First 15 Minute Quantitative Screening Method for Aflatoxin M1
8. New ROSA® WET®-S5 Aflatoxin Quantitative Test Receives USDA-GIPSA Approval
9. Highly Sensitive and Quantitative Analytical Performance is Translational for Clinical Utility of Cell-Free Tumor DNA Diagnostics
10. Shimadzu’s New Aggregates Sizer Aggregation Analysis System for Biopharmaceuticals Enables Real-time Quantitative Analysis
11. Quantitative Profiling of the Intrinsic Pathway of Apoptosis in Tumor Tissue Using Myriad RBM’s Multiplex ApoptosisMAP™, a New Biomarker Webinar by Xtalks
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/11/2017)... ... October 11, 2017 , ... ... will be hosting a Webinar titled, “Pathology is going digital. Is your lab ... digital pathology adoption best practices and how Proscia improves lab economics and realizes ...
(Date:10/11/2017)... (PRWEB) , ... October 11, 2017 , ... ... Administration (FDA) has granted orphan drug designation to SBT-100, its novel anti-STAT3 (Signal ... the treatment of osteosarcoma. SBT-100 is able to cross the cell membrane and ...
(Date:10/10/2017)... International research firm Parks Associates announced today that Tom ... 2017 Annual Meeting , October 11 in Scottsdale, Arizona ... and how smart safety and security products impact the competitive landscape. ... Parks Associates: Smart Home Devices: Main Purchase Driver ... "The residential security market has experienced continued growth, and ...
(Date:10/9/2017)... FL (PRWEB) , ... October 09, 2017 , ... The ... scheduled to broadcast first quarter 2018. American Farmer airs Tuesdays at 8:30aET on RFD-TV. ... industry is faced with the challenge of how to continue to feed a growing ...
Breaking Biology Technology:
(Date:3/27/2017)... 2017  Catholic Health Services (CHS) has been ... (HIMSS) Analytics for achieving Stage 6 on the ... In addition, CHS previously earned a place in ... electronic medical record (EMR). "HIMSS Analytics ... EMR usage in an outpatient setting.  This recognition ...
(Date:3/24/2017)... Research and Markets has announced the addition ... Trends - Industry Forecast to 2025" report to their offering. ... The Global Biometric ... of around 15.1% over the next decade to reach approximately $1,580 ... market estimates and forecasts for all the given segments on global ...
(Date:3/23/2017)... Research and Markets has announced the addition of the "Global ... 2025" report to their offering. ... The Global Vehicle Anti-Theft System Market is ... next decade to reach approximately $14.21 billion by 2025. ... all the given segments on global as well as regional levels ...
Breaking Biology News(10 mins):